Results 121 to 130 of about 2,101 (161)
Filgotinib for the treatment of rheumatoid arthritis [PDF]
Expert Opinion on Investigational Drugs, 2017 Biologics were the first targeted therapies for rheumatoid arthritis (RA), having in common high clinical efficacy. Being proteins, they are administered parenterally. The first oral targeted small molecules approved for RA are competitive inhibitors of the Janus kinase (JAK) enzyme family which mediate signalling for a cytokine subset important in RA ...
Peter C Taylor
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Filgotinib as rheumatoid arthritis therapy
Drugs of Today, 2021Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and progressive disability when inflammation cannot be sufficiently controlled. Despite treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biological DMARDs (bDMARDs), up to 30% of RA patients do not reach or fail to ...
A, Becciolini +6 more
openaire +2 more sources
Filgotinib in rheumatoid arthritis
Expert Review of Clinical Immunology, 2022Rheumatoid Arthritis (RA) remains a challenge for rheumatologists and patients despite implementation of intensive treat-to-target strategies in shared decision with patients and an increasing availability of drugs. Janus kinase inhibitors (JAKi) are a new generation of oral targeted drugs. Filgotinib preferentially inhibits JAK1 and is the latest JAKi
openaire +2 more sources
The Role of Filgotinib in Ulcerative Colitis and Crohn’s Disease
Immunotherapy, 2023Filgotinib is an oral small molecule that selectively inhibits JAK1. It is already approved for the treatment of moderately to severely active ulcerative colitis (UC). Ongoing studies are evaluating the efficacy and safety of filgotinib in Crohn's disease (CD).
Fanizza J +11 more
openaire +3 more sources
Evaluating filgotinib for the treatment of rheumatoid arthritis
Expert Opinion on Pharmacotherapy, 2021Despite the availability of an extensive armamentarium, rheumatoid arthritis (RA) remains a therapeutic challenge for rheumatologists. Janus kinase inhibitors (JAKi) are an emerging class of targeted therapies. The number of JAKi has been growing and to date, filgotinib is the latest JAKi to be approved for use in RA.This review focuses on the ...
Christophe Richez, Marie-Elise Truchetet
openaire +2 more sources
Filgotinib for moderately to severely active ulcerative colitis
Expert Review of Gastroenterology & Hepatology, 2022Filgotinib is an oral Janus kinase type 1 (JAK1) selective inhibitor with demonstrated efficacy and safety in ulcerative colitis (UC). The aim of this review is to summarize the available evidence on pharmacological characteristics, efficacy, and safety of filgotinib in UC.Pubmed, Scopus, and Embase databases were searched for all relevant studies ...
Alessandro Mannucci +4 more
openaire +2 more sources
Filgotinib for the treatment of Crohn’s disease
Expert Opinion on Investigational Drugs, 2018Inflammatory bowel diseases, such as Crohn's disease (CD) and ulcerative colitis (UC), are widespread diseases (with an estimated 2.2 million Europeans affected), and even populations previously considered 'low risk' (such as Japan and India) are witnessing an increasing incidence.
Stéphane Paul, Xavier Roblin
exaly +5 more sources
Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights
Expert Review of Clinical Pharmacology, 2021Rheumatoid arthritis (RA) is a chronic autoimmune disease, whose natural course has been deeply modified thanks to the development of new therapeutic approaches. The Janus kinase inhibitors (Jakinibs) represent the newest class of drugs introduced for treating RA.
Maria Gabriella Raimondo +5 more
openaire +2 more sources
Filgotinib for the Treatment of Refractory Collagenous Colitis
Journal of Crohn's and Colitis, 2023Tomoyoshi Shibuya, Akihito Nagahara
openaire +2 more sources